BioSpace News Archive

Influenza A Lab Results Come on Heels of Similar Findings of ClōSYS on the COVID-19 Virus, Just as U.S. Gears Up for Uncertain Flu and Cold Season [13-October-2020] SCOTTSDALE, Ariz. , Oct. 13, 2020 /PRNewswire/ -- Rowpar Pharmaceuticals, Inc., the makers of the ClōSYS brand of toothpastes, mouthwashes and oral sprays, announced today that an in vitro laboratory ana

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today the closing of its underwritten public offering of 5,637,254 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of th

Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced the appointment of Tomas Ganz , MD, PhD a

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20, 2020 at 9:30 a.m. ET. A live audio webcast of the even

Kadmon Holdings, Inc. announced that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market.

Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced the appointment of Jennie Orr as Chief Strategy and Business Officer.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis and/or Nonalcoholic Fatty Liver Disease in patients using tesamorelin.

Clyra Medical Technologies Also Joins Forces with Powerplay Retail to Ensure Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses [13-October-2020] TAMPA, Fla., Oct. 13, 2020 /PRNewswire/ -- Just in time for Amazon Prime Day, Clyra Medical Technologies, a med-tech company with deep experience fighting hospital-acquired infections, has annou

Seymour brings extensive experience in driving value-based arrangements through collaborative partnerships with providers to improve patient health and make care more affordable p

Vitro Diagnostics, Inc. announced the revocation of its SEC registration for Vitro Diagnostics, Inc while also announcing its plans for re-registration with the SEC.